Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, announced new data from a retrospective study finding that machine learning, a type of artificial intelligence (AI) that uses algorithms to find patterns in large amounts of data, may help support clinical decision-making during the programming of smart infusion pumps. The study, titled “Machine Learning Complements Smart Infusion Pump Safety Features,” was presente

Baxter Presents Data at ASHP Meeting Indicating Machine Learning May Enhance Infusion Pump Programming Safety

Abbott Labs

Chemed

West Pharmaceutical Services

Abbott Laboratories (ABT), West Pharmaceuticals Services (WST), Baxter International (BAX) and Chemed Corporation (CHE) are high-yield dividend stocks with sustainable business models.

4 MedTech Dividend Stocks in Focus on Amid Omicron Variant Panic

Automatic Data Processing

Anthem

Bank of America

Blackrock Inc

CME Group

Canadian National Railway Company

Flowers Foods

Home Depot

Coca-Cola

Lockheed Martin

NIKE

Realty Income Corp

PepsiCo

UnitedHealth Group

Walmart

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: November 30-December 12, 2021

Uber

Willis Towers

Glenview Capital Management, the firm founded by Larry Robbins (Trades, Portfolio), disclosed in November that its top five trades during the third quarter included a new holding in Willis Towers Watson PLC ( WLTW , Financial), additions to its holdings in Uber Technologies Inc. ( UBER , Financial) and Baxter International Inc. ( BAX , Financial), the closure of its stake in Walgreens Boots Alliance Inc. ( WBA , Financial) and a reduction to its holding in Tenet Healthcare Corp. ( THC , Financial).

Larry Robbins' Top 5 Trades of the 3rd Quarter

Baxter's (BAX) strategic investment to help expand the manufacturing footprint of BPS and ensure improvement in products.

Baxter's (BAX) $100M Investment to Strengthen Global Presence

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a leading global medical products company, today announced it was again named to the S&P's Dow Jones Sustainability Indices (DJSI), including both DJSI World and DJSI North America. Baxter has proudly been included in the DJSI World and DJSI North America each year since they launched, in 1999 and 2005, respectively. “Baxter's focus on corporate responsibility is inextricable from our Mission to Save and Sustain Lives,

Baxter Named to Dow Jones Sustainability Indices in Recognition of Continued Commitment to Corporate Responsibility

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter announced a $100M investment in its manufacturing facility in Halle/Westfalen, Germany that will add new capacity and capabilities.

Baxter Announces $100 Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility

DEERFIELD, Ill.--(BUSINESS WIRE)-- #digitalhealth--Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today new data showing kidney patients may experience a survival rate nearly two-times higher and a prolonged time to an adverse event (AE) and hospitalization when the Sharesource remote patient management digital health platform is used to help manage home automated peritoneal dialysis (APD).1 The new data was presented during the American Society of Nephrology's annual Kidney W

Baxter Highlights New Data Indicating Sharesource Digital Health Platform for Home Dialysis May Improve Survival and Reduce Hospitalizations

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Evercore ISI 4th Annual HealthCONx Conference on Thursday, December 2, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 9:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through May 21, 2022. About Baxter Every day, millions of patients and caregiver

Baxter to Present at Evercore ISI 4th Annual HealthCONx Conference

Baxter International Inc (NYSE: BAX) posted Q3 revenue of $3.23 billion, in line with the consensus, up 9% on a reported basis, 7% on a constant currency basis, and 6% on an operational basis. Adjusted EPS of $1.02 increased 23% and surpassed the estimate of $0.94.

Baxter Shares Fall Despite Better-Than-Expected Q3 Earnings, FY21 EPS Outlook Boost

Baxter International Inc. (BAX) CEO Joe Almeida on Q3 2021 Results - Earnings Call Transcript

Baxter's (BAX) third-quarter results reflect robust performance across all its business units.

Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates

Baxter (BAX) delivered earnings and revenue surprises of 8.51% and 0.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Baxter International (BAX) Q3 Earnings and Revenues Beat Estimates

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the third quarter of 2021. “Baxter's essential products, diverse portfolio and global scale continue to fuel our operations in 2021,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “This month marks Baxter's 90th anniversary. Our employees have been at the heart of our success for nine decades and remain as determined as ever

Baxter Reports Third-Quarter 2021 Results

Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.

Baxter (BAX) to Report Q3 Earnings: What's in the Offing?

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Baxter International (BAX) Earnings Expected to Grow: Should You Buy?

DEERFIELD, Ill. & MARCY L'ETOILE, France--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. The NEPHROCLEAR™ CCL14 Test is designed to predict persistent severe acute kidney injury (PS-AKI) and can be used to support timely clinical decision-making and care pathways. The companies intend to commercially launch the NEPHROCLEAR™ CCL1

Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on Monday, November 8, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 8:50 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through November 7, 2022. About Baxter Every day, millions of patients a

Baxter to Present at Credit Suisse 30th Annual Virtual Healthcare Conference

We believe that Baxter stock is a good buying opportunity at the present time. BAX stock trades near $81 currently and it is, in fact, down 13% from its pre-Covid high of $93 in February 2020 – just before the coronavirus pandemic hit the world.

Should You Buy Baxter Stock Around $80?

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter presents critical care data at European Society of Intensive Care Medicine (ESICM) LIVES congress

Baxter Presents Critical Care Data at 34th Annual European Society of Intensive Care Medicine LIVES Congress

Boston Scientific

Catalent

Hill-Rom Hlds

Medtronic

Intersect ENT

MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.

MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its third-quarter 2021 financial results on Thursday, October 28, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/3534264 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxt

Baxter to Host Third-Quarter 2021 Financial Results Conference Call for Investors

Baxter's (BAX) norepinephrine can improve speed, efficiency and safety of treatment during critical care situations in hospital settings, and minimize compounding errors or touch contamination risks.

Baxter's (BAX) Premix Norepinephrine Now Available in U.S.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter announced the U.S. FDA approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine).

Baxter Announces U.S. FDA Approval and Launch of Ready-to-use Cardiovascular Medicine Norepinephrine in Premix Formulation

Colgate-Palmolive

Con Ed

Hormel Foods

Kellogg

Altria

Novartis

Northwest Natural Gas

Pinnacle West Capital

Reckitt Benckiser Group PLC

Unilever

Verizon

The market is 30% overvalued, and September is historically a time when many corrections begin. Fortunately, there are plenty of high-yield/low volatility blue chips to choose from.

News for Baxter Stock (BAX)